{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:41Z","timestamp":1790188301162,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"DOI":"10.7759\/cureus.78555","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:43:46Z","timestamp":1738773826000},"source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes"],"prefix":"10.7759","author":[{"given":"Sri Ram Charan","family":"Gundapaneni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithwik Goud","family":"Burri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiturgan","family":"Mamytova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poshitha","family":"Kondadasula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugolbai","family":"Tagaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-819751-6.00003-7","article-title":"Risk factors of obesity","author":"Moini J","year":"2020","unstructured":"Moini J, Ahangari R, Samsam M, Miller C. Risk factors of obesity. Global Health Complications of Obesity. Elsevier, New York, NY; 2020. 29-40. 10.1016\/b978-0-12-819751-6.00003-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21460\/bikdw.v7i1.531","article-title":"Obesity genetics","volume":"7","author":"Wicaksono H","year":"2022","unstructured":"Wicaksono H. Obesity genetics. Berkala Ilmiah Kedokteran Duta Wacana. 2022, 7:26. 10.21460\/bikdw.v7i1.531","journal-title":"Berkala Ilmiah Kedokteran Duta Wacana"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutos.2022.08.007","article-title":"Correlation between dietary intake and obesity risk factors among healthy adults","volume":"45","author":"Shatwan IM","year":"2022","unstructured":"Shatwan IM, Almoraie NM. Correlation between dietary intake and obesity risk factors among healthy adults. Clin Nutr Open Sci. 2022, 45:32-41. 10.1016\/j.nutos.2022.08.007","journal-title":"Clin Nutr Open Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000447","article-title":"Obesity and genetics","volume":"32","author":"Golden A","year":"2020","unstructured":"Golden A, Kessler C. Obesity and genetics. J Am Assoc Nurse Pract. 2020, 32:493-6. 10.1097\/JXX.0000000000000447","journal-title":"J Am Assoc Nurse Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12775\/jehs.2024.60.012","article-title":"Childhood obesity\u2014risk factors and prevention strategies","volume":"60","author":"Magiera B","year":"2024","unstructured":"Magiera B, Razik W, Ramian J, et al.. Childhood obesity\u2014risk factors and prevention strategies. J Educ Health Sport. 2024, 60:175-87. 10.12775\/jehs.2024.60.012","journal-title":"J Educ Health Sport"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1109\/bhi.2018.8333449","article-title":"Obesity risk factors ranking using multi-task learning","author":"Wang L","year":"2018","unstructured":"Wang L, Towner E, Dong M, Zhu D. Obesity risk factors ranking using multi-task learning. Inst Electr Electron Eng. 2018, 10.1109\/bhi.2018.8333449","journal-title":"Inst Electr Electron Eng"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0016","article-title":"Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach","volume":"34","author":"Isaacs DM","year":"2021","unstructured":"Isaacs DM, Kruger DF, Spollett GR. Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. Diabetes Spectr. 2021, 34:7-19. 10.2337\/ds20-0016","journal-title":"Diabetes Spectr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau J","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015, 58:7370-80. 10.1021\/acs.jmedchem.5b00726","journal-title":"J Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.21052","article-title":"New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus(\u00ae) tablets), an oral GLP-1 receptor agonist (Article in Japanese)","volume":"157","author":"Miyasaka K","year":"2022","unstructured":"Miyasaka K. New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus(\u00ae) tablets), an oral GLP-1 receptor agonist (Article in Japanese). Nihon Yakurigaku Zasshi. 2022, 157:146-54. 10.1254\/fpj.21052","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz042","article-title":"Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity","volume":"4","author":"Iacobellis G","year":"2020","unstructured":"Iacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020, 4:bvz042. 10.1210\/jendso\/bvz042","journal-title":"J Endocr Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0444","article-title":"Greater combined reductions in hba1c \u22651.0% and weight \u22655.0% with semaglutide versus comparators in type 2 diabetes","volume":"25","author":"Rodbard HW","year":"2019","unstructured":"Rodbard HW, Bellary S, Hramiak I, et al.. Greater combined reductions in hba1c \u22651.0% and weight \u22655.0% with semaglutide versus comparators in type 2 diabetes. Endocr Pract. 2019, 25:589-97. 10.4158\/EP-2018-0444","journal-title":"Endocr Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.09.002","article-title":"Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"45","author":"Mishriky BM","year":"2019","unstructured":"Mishriky BM, Cummings DM, Powell JR, Sewell KA, Tanenberg RJ. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2019, 45:102-9. 10.1016\/j.diabet.2018.09.002","journal-title":"Diabetes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000351","article-title":"Semaglutide: a novel oral glucagon-like peptide receptor agonist for the treatment of type 2 diabetes mellitus","volume":"29","author":"Chan M","year":"2021","unstructured":"Chan M, Dimitriou A, Lam S. Semaglutide: a novel oral glucagon-like peptide receptor agonist for the treatment of type 2 diabetes mellitus. Cardiol Rev. 2021, 29:100-8. 10.1097\/CRD.0000000000000351","journal-title":"Cardiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019889064","article-title":"Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"54","author":"Cowart K","year":"2020","unstructured":"Cowart K. Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2020, 54:478-85. 10.1177\/1060028019889064","journal-title":"Ann Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman B","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al.. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019, 7:356-67. 10.1016\/S2213-8587(19)30066-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022, 39:1233-48. 10.1007\/s11095-022-03302-1","journal-title":"Pharm Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.09.054","article-title":"Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis","volume":"81","author":"Chang YF","year":"2020","unstructured":"Chang YF, Zhang D, Hu WM, Liu DX, Li L. Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020, 81:234-9. 10.1016\/j.jocn.2020.09.054","journal-title":"J Clin Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner RF","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, et al.. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020, 28:1050-61. 10.1002\/oby.22794","journal-title":"Obesity (Silver Spring)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz072","article-title":"Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials","volume":"105","author":"DeSouza C","year":"2020","unstructured":"DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J Clin Endocrinol Metab. 2020, 105:10.1210\/clinem\/dgz072","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13396","article-title":"Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme","volume":"20","author":"DeVries JH","year":"2018","unstructured":"DeVries JH, Desouza C, Bellary S, Unger J, Hansen OK, Zacho J, Woo V. Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. Diabetes Obes Metab. 2018, 20:2426-34. 10.1111\/dom.13396","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton S","year":"2022","unstructured":"Wharton S, Calanna S, Davies M, et al.. Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022, 24:94-105. 10.1111\/dom.14551","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley RE","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, Viljoen A. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6:275-86. 10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil PM","year":"2018","unstructured":"O'Neil PM, Birkenfeld AL, McGowan B, et al.. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018, 392:637-49. 10.1016\/S0140-6736(18)31773-2","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n B","year":"2018","unstructured":"Ahr\u00e9n B, Atkin SL, Charpentier G, et al.. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018, 20:2210-9. 10.1111\/dom.13353","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13816","article-title":"Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials","volume":"21","author":"Jendle J","year":"2019","unstructured":"Jendle J, Birkenfeld AL, Polonsky WH, et al.. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. Diabetes Obes Metab. 2019, 21:2315-26. 10.1111\/dom.13816","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa577","article-title":"Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis","volume":"105","author":"Lingvay I","year":"2020","unstructured":"Lingvay I, Capehorn MS, Catarig AM, et al.. Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis. J Clin Endocrinol Metab. 2020, 105:e4593-604. 10.1210\/clinem\/dgaa577","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02802-5","article-title":"GADD45\u03b1 drives brown adipose tissue formation through upregulating PPAR\u03b3 in mice","volume":"11","author":"You W","year":"2020","unstructured":"You W, Xu Z, Sun Y, Valencak TG, Wang Y, Shan T. GADD45\u03b1 drives brown adipose tissue formation through upregulating PPAR\u03b3 in mice. Cell Death Dis. 2020, 11:585. 10.1038\/s41419-020-02802-5","journal-title":"Cell Death Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00796-z","article-title":"Once-weekly semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background common OAD: A subgroup analysis from SUSTAIN 2-4 and 10","volume":"11","author":"Capehorn M","year":"2020","unstructured":"Capehorn M, Ghani Y, Hindsberger C, Johansen P, J\u00f3dar E. Once-weekly semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background common OAD: A subgroup analysis from SUSTAIN 2-4 and 10. Diabetes Ther. 2020, 11:1061-75. 10.1007\/s13300-020-00796-z","journal-title":"Diabetes Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-00955-7","article-title":"Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist","volume":"46","author":"Pontes-da-Silva RM","year":"2022","unstructured":"Pontes-da-Silva RM, de Souza Marinho T, de Macedo Cardoso LE, Mandarim-de-Lacerda CA, Aguila MB. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. Int J Obes (Lond). 2022, 46:21-9. 10.1038\/s41366-021-00955-7","journal-title":"Int J Obes (Lond)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221092681","article-title":"Once-weekly semaglutide for weight management: a clinical review","volume":"38","author":"Fornes A","year":"2022","unstructured":"Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022, 38:239-46. 10.1177\/87551225221092681","journal-title":"J Pharm Technol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000430","article-title":"Semaglutide for weight loss: was it worth the weight?","volume":"30","author":"Novograd J","year":"2022","unstructured":"Novograd J, Mullally J, Frishman WH. Semaglutide for weight loss: was it worth the weight?. Cardiol Rev. 2022, 30:324-9. 10.1097\/CRD.0000000000000430","journal-title":"Cardiol Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?","volume":"24","author":"Pedrosa MR","year":"2022","unstructured":"Pedrosa MR, Franco DR, Gieremek HW, et al.. GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?. Curr Atheroscler Rep. 2022, 24:867-84. 10.1007\/s11883-022-01062-2","journal-title":"Curr Atheroscler Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro V","year":"2022","unstructured":"Pirro V, Roth KD, Lin Y, et al.. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022, 107:363-78. 10.1210\/clinem\/dgab722","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336293-semaglutide-in-obesity-and-type-2-diabetes-management-a-systematic-review-of-clinical-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:43:49Z","timestamp":1738773829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336293-semaglutide-in-obesity-and-type-2-diabetes-management-a-systematic-review-of-clinical-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.78555","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}